P2Y12 inhibitor use was not associated with risk of incident CRC but was significantly inversely associated with CRC mortality, which appeared to be due to improved survival among individuals who initiate P2Y12 inhibitors after CRC diagnosis.
Key Findings
Results
P2Y12 inhibitor use was not associated with colorectal cancer incidence in patients with atherosclerotic cardiovascular disease.
Study population included 334,882 patients diagnosed with ASCVD between 2006 and 2021 from the ESPRESSO cohort.
4,015 incident CRC cases were documented during a median follow-up of 5.1 years (IQR, 2.1-9.0 years).
Cox proportional-hazards regression models were used, adjusting for comorbidities and regular aspirin use.
P2Y12 inhibitor use was defined as initiation of ≥84 consecutive Defined Daily Doses (cDDDs).
Results
Longer duration of P2Y12 inhibitor use was associated with lower CRC-related mortality compared to non-users.
2,610 CRC-related deaths were documented during the follow-up period.
Patients with 336-671 cDDDs of P2Y12 inhibitor had a multivariable-adjusted HR for CRC mortality of 0.73 (95% CI, 0.60-0.89).
Patients with ≥672 cDDDs had a multivariable-adjusted HR for CRC mortality of 0.81 (95% CI, 0.68-0.97).
The association showed a duration-dependent pattern, with the strongest inverse association in the intermediate dose group.
Results
Initiation of P2Y12 inhibitors after a colorectal cancer diagnosis was associated with significantly lower CRC-related mortality.
Among patients with incident CRC diagnosis, subsequent initiation of P2Y12 inhibitor after CRC diagnosis was associated with an HR of 0.42 (95% CI, 0.29-0.60).
This finding suggests the observed survival benefit may be driven primarily by post-diagnosis use rather than pre-diagnosis use.
The authors note this finding merits further study given the observational nature of the analysis and potential for residual confounding.
Methods
The study was a registry-based cohort study drawn from the ESPRESSO cohort of ASCVD patients in Sweden.
Patients were diagnosed with ASCVD between 2006 and 2021.
Median follow-up was 5.1 years (IQR, 2.1-9.0 years).
P2Y12 inhibitor exposure was defined by ≥84 consecutive Defined Daily Doses.
Analyses adjusted for potential confounders including comorbidities and regular aspirin use.
Low-dose aspirin use, which has a known association with reduced CRC incidence and mortality, was included as a covariate.
Discussion
The inverse association between P2Y12 inhibitor use and CRC mortality appeared to be primarily explained by improved survival among individuals who initiated P2Y12 inhibitors after CRC diagnosis.
Pre-diagnosis P2Y12 inhibitor use did not show the same magnitude of association as post-diagnosis use.
Post-diagnosis initiation was associated with HR 0.42 (95% CI, 0.29-0.60) for CRC mortality.
The authors acknowledge the observational nature of the study and potential for residual confounding as important limitations.
The authors state these findings 'merit further study.'
What This Means
This research suggests that a class of blood-thinning medications called P2Y12 inhibitors (commonly used after heart attacks and strokes to prevent blood clots) may be linked to better survival outcomes in people who develop colorectal cancer, but does not appear to reduce the chances of getting colorectal cancer in the first place. The study followed over 334,000 Swedish patients with cardiovascular disease for a median of about five years, tracking who developed colorectal cancer and who died from it. Patients who used P2Y12 inhibitors for longer durations had a 19-27% lower risk of dying from colorectal cancer compared to non-users, and those who started taking these medications after a colorectal cancer diagnosis had a particularly striking 58% lower risk of colorectal cancer death.
The most notable finding was that the survival benefit seemed to be concentrated among people who began taking P2Y12 inhibitors after their colorectal cancer was diagnosed, rather than those who were already on the medication beforehand. This suggests the drugs may have an effect on cancer progression or tumor biology, rather than preventing cancer from forming in the first place. The mechanism could relate to the role platelets play in helping cancer cells survive and spread in the body, though the study did not test this directly.
Because this was an observational study — meaning researchers observed what happened naturally rather than conducting a controlled experiment — there is a possibility that other unmeasured factors could explain the results. The authors themselves caution that residual confounding (hidden differences between groups) may have influenced the findings. This research suggests that P2Y12 inhibitors warrant further investigation in the context of colorectal cancer treatment, potentially through randomized clinical trials that could more definitively establish whether these widely-used cardiovascular drugs have a genuine anti-cancer effect.
Fuchs M, Ha J, Yan J, Bottai M, Song M, Simon T, et al.. (2026). Platelet P2Y12 inhibitor use and risk of colorectal cancer incidence and colorectal cancer-related mortality: a Swedish registry-based cohort study.. BMC gastroenterology. https://doi.org/10.1186/s12876-026-05422-z